Evaluation of the Pharmacokinetics of NRL972 Following Pre-Administration of Rifampicin and Cyclosporine

Phase 1

Completed

• Conditions: Pharmacokinetics
• Interventions: Drug: NRL972

• Registration Number: NCT00856752
• Lead Sponsor: Norgine

Brief Summary

A study in healthy volunteers to determine whether different drugs metabolised by the liver have any effects on how NRL972 is processed within the body.

Detailed Description

Not available

Study Timeline

• Study Start: 2006-06
• Primary Completion: 2006-07
• Study Completion: 2006-08
• Status Verified: 2009-03
• Study First Submitted: 2009-03-05
• Study First Submitted QC: 2009-03-05
• Last Update Submitted: 2009-03-05
• Study First Posted: 2009-03-06
• Last Update Posted: 2009-03-06

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 12

Inclusion Criteria

1. Males or females (females of non-childbearing potential or of childbearing potential while taking medically appropriate contraception)
2. Caucasian
3. Age: 21 - 40 years
4. BW 50 - 100 kg
5. BMI 20 - 26 kg.m-2
6. healthy based on the pre-study examination
7. willing and able to provide informed consent

Exclusion Criteria

General - all subjects

1. Previous participation in the trial

2. Participant in any other trial during the last 90 days

3. Donation of blood during the last 60 days or a history of blood loss exceeding 300 mL within the last 3 months

4. History of any clinically relevant allergy (including hypersensitivity to the trial medications)

5. Presence of acute or chronic infection

6. Presence or history of any relevant co-morbidity

7. Resting systolic blood pressure > 160 or < 90 mmHg, diastolic blood pressure > 95 or < 50 mmHg

8. Clinically relevant ECG-abnormalities, prolonged QTc with > 450 msec in males and > 460 msec in females in particular

9. Presence of any relevant abnormality in the laboratory safety tests, especially low haemoglobin, increased liver enzymes

10. Positive serology for HBsAg, anti HBc and anti HCV

11. Positive HIV test

12. Positive alcohol or urine drug test on recruitment (and upon admission)

13. History of alcohol and/or drug abuse and/or daily use of > 30 gr alcohol

14. Smoking more than 15 cigarettes/day or equivalent of other tobacco products

15. Use of prohibited medication

16. Suspicion or evidence that the subject is not trustworthy and reliable

17. Suspicion or evidence that the subject is not able to make a free consent or to understand the information in this regard

    General - all females

18. Positive pregnancy test

19. Lactating

20. Not using appropriate contraception in pre-menopausal women (note: under the conditions of the present study, women using hormonal contraceptives will be informed that this method is not sufficient during the study and that further i.e. mechanical methods [condom, diaphragm with spermacide gel] should be used in addition).

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
T1	NRL972	Pre-treatment with rifampicin
T2	NRL972	Pre-treatment with cyclosporin
Reference	NRL972	Administration of NRL001 alone: no pre-treatment

Primary Outcome Measures

Name	Time	Method
Total clearance by non-compartmental analysis. Apparent terminal disposition half-life t½ by non-compartmental analysis	Up to 6 hours post dose

Secondary Outcome Measures

Name	Time	Method
Non-compartmental PK-analysis based on the extensive profile (up to last quantifiable data point), the 'short' profile (over the first hour after injection), and the two-point profile based on selected data-pairs over the 1st hour after dosing	Up to 6 hours post dose

Trial Locations

Locations (1)

Dept. Clinical Pharmacology & Therapeutics, MHAPT "Zaritza Johanna" University Hospital; 🇧🇬 Sofia, Bulgaria